Jefferies initiates coverage on Sartorius AG stock with Buy rating

Jefferies initiated coverage on Sartorius AG (ETR:SATG) with a Buy rating and a EUR210.00 price target, highlighting the company's complex structure accessible via ordinary shares (SRT), preference shares (SRT3), and Sartorius Stedim Biotech (DIM). The firm's analysis focuses on ownership implications ahead of 2028 heirship changes, anticipating increased investor scrutiny on the relative value between Sartorius' preference shares and Sartorius Stedim Biotech.

Analysis

Jefferies has initiated coverage on Sartorius AG with a 'Buy' rating and a price target of EUR 210.00, signaling a bullish outlook. The core of the analysis centers on the company's complex corporate structure and a key long-term catalyst. Sartorius AG consolidates its subsidiary, Sartorius Stedim Biotech, in which it holds approximately 71.5% of shares and 83% of voting rights. Investors can gain exposure through three distinct securities: ordinary shares (SRT), preference shares (SRT3), and the separately listed Sartorius Stedim Biotech shares (DIM). Jefferies' decision to cover the illiquid ordinary shares is strategically aimed at assessing ownership implications tied to a significant change in the company's joint heirship structure expected in 2028. Consequently, the firm anticipates that the relative valuation between Sartorius' preference shares and Sartorius Stedim Biotech shares will become an increasingly important theme for investors, suggesting a potential for value arbitrage or convergence plays.

Key Decisions for Investors

• Given the new 'Buy' rating and a EUR 210.00 price target from Jefferies, investors should consider Sartorius AG as a potential long position, particularly if they are bullish on the biopharmaceutical equipment sector.
• Sophisticated investors should analyze the valuation and liquidity differentials between Sartorius's ordinary shares (SRT), preference shares (SRT3), and the Sartorius Stedim Biotech (DIM) listing, as the relative value trade between these instruments is highlighted as a key future investment theme.
• Long-term holders should monitor any news or disclosures related to the company's joint heirship arrangement, as its resolution in 2028 is a fundamental catalyst underpinning Jefferies' positive thesis.